Dyslipidemias
Conditions
Keywords
CKD-391
Brief summary
A clinical trial to compare and evaluate the safety and pharmacokinetics of CKD-391
Detailed description
A phase I clinical trial to compare and evaluate the safety and pharmacokinetic characteristics after administration of CKD-391 and co-administration of CKD-331 and D337 in healthy adult volunteers
Interventions
DRUGDrug: CKD-391, QD, PO
Drug: CKD-331, D337 QD, PO
Sponsors
Chong Kun Dang Pharmaceutical
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy adult aged between 19 to 55 at screening 2. Weight ≥ 50kg(man) or 45kg(woman), with calculated body mass index (BMI) of 18 to 30kg/m2 3. Those who have no clinically significant congenital or chronic diseases and have no abnormal symptoms of findings 4. Those who are deemed suitable for clinical trials based on laboratory (hematology, blood chemistry, serology, urinalysis, urine drug test) and 12-lead ECG results at screening 5. Those who agree to contraception from the first IP dosing day till 14 days after the last dosing day and decide not to provide sperm during the participation of clinical trial 6. Those who voluntarily decide to participate in paper and agree to comply with the cautions after fully understand the detailed description of this clinical trial
Exclusion criteria
1. Those who have used drugs that induce or inhibit drug metabolizing enzymes, such as barbiturates, within 1 month before the first dosing date, or who have used drugs that may interfere with this study within 10 days before the first dosing day 2. Those who exceed an alcohol, caffeine and cigarette consumption (caffeine\> 5 cups/day, alcohol\> 21 glasses/week(man), 14 glasses/week(woman), smoking\> 20 cigarettes/day) and not able to stop on smoking, caffeine and alcohol 3. Those who received investigational products or participated in bioequivalence test within 6 months before the first administration of clinical trial drugs 4. Those who donated whole blood within 8 weeks before the first date of administration and donated ingredients within 2 weeks or received blood transfusion in 4 weeks 5. Those who have a history of gastrointestinal surgery except simple appendectomy and hernia surgery 6. Patients with the following diseases * Patients with active liver disease or with elevated amino transferase levels with unknown cause increased by more than 3 times the normal upper limit * Patients with severe liver failure or biliary obstruction and bile congestion * Patients with muscular disease, rhabdomyolysis, or persons with a past history * Patients with hypothyroidism, patients with genetic muscle disease or their family history, and patients with history of muscle disability due to drugs * Patients with renal impairment or a history of in and patients with severe renal dysfunction * Patients with a history of muscle toxicity to other statin drugs or fibrate drugs 7. Those who have genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption 8. Those who have hypersensitivity to the main constituents or components of the investigational drug 9. Those who have a history of drug abuse within 1 year of screening or who have tested positive for urine drug tests 10. Woman who are pregnant or breastfeeding 11. Those who are deemed insufficient to participate in clinical study by investigators
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Primary Outcome Measure | Pre-dose(0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72hours | AUCt of CKD-391: Area under the concentration-time curve time zero to time |
Countries
South Korea
Outcome results
None listed